|
|
||||||||
J Thorac Cardiovasc Surg 1994;107:1155-1156
© 1994 Mosby, Inc.
LETTERS TO THE EDITOR |
Department of Cardiothoracic Surgery
Northern General Hospital
Sheffield, England
To the Editor:
Jett and colleagues
1 compared the ability of different vasodilators to prevent contraction of segments of human internal mammary artery in vitro. We similarly compared the ability of vasodilators to relax potassium-constricted artery, but we caution against extrapolating the results to the clinical situation.
Thirty-two rings of left internal mammary artery from above the bifurcation were provided by 17 patients. There were no significant differences in preoperative drug treatment between patients. Rings were mounted in an organ bath containing oxygenated, modified Krebs buffer at 37° C. Each ring was set at a resting tension equivalent to that required to stretch the ring to 90% of its internal circumference when distended by a transmural pressure of 100 mm Hg2 and then contracted with potassium 25 mmol/L. Concentration response curves were constructed for nifedipine, sodium nitroprusside, glyceryl trinitrate, and papaverine.
At a concentration of -4 logM units each agent produced almost full relaxation (Fig. 1). However, there were significant differences in the potencies of the four agents (Table I).
|
|
These differences in the in vitro ability of vasodilators to prevent contraction of internal mammary artery or to relax precontracted internal mammary artery are of interest. More relevant, however, if this work is aimed at identifying a clinically useful dilator, is the difference between the in vitro and in vivo responses. In a clinical study, free flow through the internal mammary artery was measured before and after topical application of papaverine (-2.40 logM), glyceryl trinitrate (-2.66 logM), nifedipine (-3.54 logM), and sodium nitroprusside (-2.77 logM).
4 Sodium nitroprusside produced a significantly greater increase in flow than did the other agents. Our studies suggest that sodium nitroprusside is a potent agent in vivo, but more important it is of superior potency in the clinical situation.
References
This article has been cited by other articles:
![]() |
F. L. Rosenfeldt, G.-W. He, B. F. Buxton, and J. A. Angus Pharmacology of coronary artery bypass grafts Ann. Thorac. Surg., March 1, 1999; 67(3): 878 - 888. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |